Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.98 +1.53 (+2.76%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,914,280
Open 56.71
Bid (Size) 56.99 (1)
Ask (Size) 57.11 (3)
Prev. Close 55.45
Today's Range 56.64 - 57.51
52wk Range 45.05 - 139.74
Shares Outstanding N/A
Dividend Yield 3.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Warren Buffett Makes a Big Buy
Berkshire Hathaway bought $1.6 billion of United Health stock in Q2. Inflation may be ticking higher after all. 
Via The Motley Fool
Topics Economy
Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity
Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock. 
Via Benzinga

Performance

YTD
-34.9%
-34.9%
1 Month
-19.4%
-19.4%
3 Month
-19.1%
-19.1%
6 Month
-37.1%
-37.1%
1 Year
-58.4%
-58.4%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End
Via Stocktwits
Health Canada Approves Novo’s Ozempic to Reduce Risk Of Kidney Function Decline, Cardiovascular Death
Via Stocktwits
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Congressional Trading Report: Rep. Marjorie Taylor Greene Bought Over $15K In Novo Nordisk Stock
Via Benzinga
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know
Via The Motley Fool
Dow Futures Decline As Fed Minutes Point To Inflation Anxiety: WMT, META, PLTR, NVO Among Stocks To Watch
Via Stocktwits
Topics Economy Stocks
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny
Via MarketMinute
Topics Artificial Intelligence
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
Via MarketMinute
Topics Artificial Intelligence Economy
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats
Via Benzinga
Topics Workforce
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year
Via Stocktwits
1 Reason to Buy NVO
Via The Motley Fool
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Via Benzinga
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
Via MarketMinute

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 56.98
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/22/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.